REGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium
06 juil. 2017 16h05 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., July 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
07 juin 2017 16h01 HE
|
REGENXBIO Inc.
ROCKVILLE, Md. and CHICAGO, Ill., June 07, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (NASDAQ:RGNX) and AveXis, Inc. (NASDAQ:AVXS) today announced an exclusive worldwide license agreement for AveXis to...
REGENXBIO Announces Initiation of Phase I Clinical Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
31 mai 2017 07h00 HE
|
REGENXBIO Inc.
Clinical trial evaluates one-time treatment for wet AMD using NAV® AAV8 gene therapy; interim trial update expected late 2017 ROCKVILLE, Md., May 31, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc....
REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
10 mai 2017 16h05 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., May 10, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
09 mai 2017 16h01 HE
|
REGENXBIO Inc.
On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017 and continuing enrollment of patients in RGX-501 Phase I/II trial for HoFHInterim trial updates for RGX-314 and...
Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
04 mai 2017 16h06 HE
|
REGENXBIO Inc.
Preclinical data for RGX-314 program for the treatment of wet AMD to be presented at the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and...
REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
02 mai 2017 16h05 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., May 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...
REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
26 avr. 2017 16h01 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., April 26, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
REGENXBIO Enhances and Expands Scientific Leadership
28 mars 2017 07h00 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...
REGENXBIO Announces Pricing of Public Offering of Common Stock
21 mars 2017 21h30 HE
|
REGENXBIO Inc.
ROCKVILLE, Md., March 21, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene...